160 related articles for article (PubMed ID: 29381773)
1. Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease.
Moradi N; Fadaei R; Emamgholipour S; Kazemian E; Panahi G; Vahedi S; Saed L; Fallah S
PLoS One; 2018; 13(1):e0192159. PubMed ID: 29381773
[TBL] [Abstract][Full Text] [Related]
2. Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes.
Chu CS; Lee KT; Cheng KH; Lee MY; Kuo HF; Lin TH; Su HM; Voon WC; Sheu SH; Lai WT
Cardiovasc Diabetol; 2012 Mar; 11():21. PubMed ID: 22397368
[TBL] [Abstract][Full Text] [Related]
3. CCN3/NOV serum levels in coronary artery disease (CAD) patients and its correlation with TNF-α and IL-6.
Fadhil Jaafar A; Afrisham R; Fadaei R; Farrokhi V; Moradi N; Abbasi A; Einollahi N
BMC Res Notes; 2023 Nov; 16(1):306. PubMed ID: 37919772
[TBL] [Abstract][Full Text] [Related]
4. Serum Irisin Levels, Endothelial Dysfunction, and Inflammation in Pediatric Patients with Type 2 Diabetes Mellitus and Metabolic Syndrome.
Huerta-Delgado AS; Roffe-Vazquez DN; Gonzalez-Gil AM; Villarreal-Calderón JR; Tamez-Rivera O; Rodriguez-Gutierrez NA; Castillo EC; Silva-Platas C; Garcia-Rivas G; Elizondo-Montemayor L
J Diabetes Res; 2020; 2020():1949415. PubMed ID: 32964051
[TBL] [Abstract][Full Text] [Related]
5. Association Between Serum Uric Acid Levels and Oxido-Inflammatory Biomarkers With Coronary Artery Disease in Type 2 Diabetic Patients.
Gharib AF; Nafea OE; Alrehaili AA; Almalki A; Alharthi A; Alsalmi O; Alsaeedi FA; Alhazmi A; Allahyani M; Etewa RL; Alsulimani AH; Badr SO
Cureus; 2023 Oct; 15(10):e47913. PubMed ID: 38034261
[TBL] [Abstract][Full Text] [Related]
6. Role of C1q/TNF-Related Protein 6 for the Evaluation of Coronary Heart Disease Associated with Type 2 Diabetes.
Li M; Zhou S; Feng Z; Zhang C
Ther Clin Risk Manag; 2024; 20():289-296. PubMed ID: 38799512
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6 and uric acid among type 2 diabetes mellitus patients with coronary artery disease.
Chittaragi GH; Ambali AP; Honnutagi R; Ganesh V
Bioinformation; 2023; 19(12):1134-1138. PubMed ID: 38250529
[TBL] [Abstract][Full Text] [Related]
8. Platelet Mediated Inflammation in Coronary Artery Disease with Type 2 Diabetes Patients.
Johny E; Bhaskar P; Alam MJ; Kuladhipati I; Das R; Adela R
J Inflamm Res; 2021; 14():5131-5147. PubMed ID: 34675593
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiles associated with coronary artery disease in type 2 diabetes mellitus.
Nevado JB; Cutiongco-de la Paz EMC; Paz-Pacheco ET; Jasul GV; Aman AYCL; Deguit CDT; San Pedro JVB; Francisco MDG
Front Endocrinol (Lausanne); 2024; 15():1323168. PubMed ID: 38706700
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.
Randeria SN; Thomson GJA; Nell TA; Roberts T; Pretorius E
Cardiovasc Diabetol; 2019 Jun; 18(1):72. PubMed ID: 31164120
[TBL] [Abstract][Full Text] [Related]
11. Multiplex analysis of inflammatory proteins associated with risk of coronary artery disease in type-1 diabetes patients.
Beatty C; Richardson KP; Tran PMH; Satter KB; Hopkins D; Gardiner M; Sharma A; Purohit S
Clin Cardiol; 2024 Jan; 47(1):e24143. PubMed ID: 37822049
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the metabolic divide: distinctive metabolites differentiating CAD-T2DM from CAD patients.
Liu Y; Liu JE; He H; Qin M; Lei H; Meng J; Liu C; Chen X; Luo W; Zhong S
Cardiovasc Diabetol; 2024 Jan; 23(1):14. PubMed ID: 38184583
[TBL] [Abstract][Full Text] [Related]
13. VDR downregulation and promoter hypermethylation as one of the causes for triggering type 2 diabetes mellitus: Clinical and molecular studies.
Tarfeen N; Masoodi SR; Nisa KU; Ali S; Ahmad MB; Ganai BA
J Diabetes Metab Disord; 2023 Dec; 22(2):1443-1451. PubMed ID: 37975142
[TBL] [Abstract][Full Text] [Related]
14. The Association of Serum Complement C1q with Coronary Artery Disease: A Systematic Review and Meta-Analysis.
Jia P; Wu Y; Gong Y; Jia Y; Wu X; Jian G
Altern Ther Health Med; 2024 Apr; ():. PubMed ID: 38607203
[TBL] [Abstract][Full Text] [Related]
15. Association of C1q/TNF-Related Protein-9 (CTRP9) Level with Obstructive Sleep Apnea in Patients with Coronary Artery Disease.
Li Z; Du Y; Jia L; Fan J; Guo R; Ma X; Wang X; Nie S; Wei Y
Mediators Inflamm; 2020; 2020():7281391. PubMed ID: 32831639
[TBL] [Abstract][Full Text] [Related]
16. C1q/TNF-related protein-9 attenuates atherosclerosis through AMPK-NLRP3 inflammasome singling pathway.
Zhang H; Gong X; Ni S; Wang Y; Zhu L; Ji N
Int Immunopharmacol; 2019 Dec; 77():105934. PubMed ID: 31727560
[TBL] [Abstract][Full Text] [Related]
17. CTRP9 Ameliorates Atrial Inflammation, Fibrosis, and Vulnerability to Atrial Fibrillation in Post-Myocardial Infarction Rats.
Liu M; Li W; Wang H; Yin L; Ye B; Tang Y; Huang C
J Am Heart Assoc; 2019 Nov; 8(21):e013133. PubMed ID: 31623508
[TBL] [Abstract][Full Text] [Related]
18. A Review of the Relationship Between CTRP Family and Coronary Artery Disease.
Si Y; Fan W; Sun L
Curr Atheroscler Rep; 2020 May; 22(6):22. PubMed ID: 32468164
[TBL] [Abstract][Full Text] [Related]
19. Cardiac-derived CTRP9 protects against myocardial ischemia/reperfusion injury via calreticulin-dependent inhibition of apoptosis.
Zhao D; Feng P; Sun Y; Qin Z; Zhang Z; Tan Y; Gao E; Lau WB; Ma X; Yang J; Yu S; Xu X; Yi D; Yi W
Cell Death Dis; 2018 Jun; 9(7):723. PubMed ID: 29925877
[TBL] [Abstract][Full Text] [Related]
20. The C1q/TNF-related proteins (CTRPs) in pathogenesis of obesity-related metabolic disorders: Focus on type 2 diabetes and cardiovascular diseases.
Shanaki M; Shabani P; Goudarzi A; Omidifar A; Bashash D; Emamgholipour S
Life Sci; 2020 Sep; 256():117913. PubMed ID: 32526287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
